[Comment] AKT-targeted triplet therapy in advanced breast cancer
Summary
The advent of CDK4/6 inhibitors combined with endocrine therapy has substantially transformed the treatment approach for patients with HR+/HER2– metastatic breast cancer;1 however, acquired resistance inevitably develops, making the optimal sequencing of subsequent targeted therapies a substantial challenge. Aberrant activation of the PI3K/AKT/PTEN signalling axis is frequently identified as a key contributor to CDK…
The advent of CDK4/6 inhibitors combined with endocrine therapy has substantially transformed the treatment approach for patients with HR+/HER2– metastatic breast cancer;1 however, acquired resistance inevitably develops, making the optimal sequencing of subsequent targeted therapies a substantial challenge. Aberrant activation of the PI3K/AKT/PTEN signalling axis is frequently identified as a key contributor to CDK4/6 inhibitor cross-resistance, providing a robust biological rationale for therapeutic intervention.